# Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer

> **NCT04901754** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 38 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Camrelizumab Plus Apatinib

## Key facts

- **NCT ID:** NCT04901754
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-14
- **Primary completion:** 2022-08-15
- **Final completion:** 2023-03-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901754, "Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04901754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*